InterWest Venture Management’s Xenon Pharmaceuticals XENE Stock Holding History

InterWest Venture Management’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-8,293	Closed	-$127K	–	10
2021 Q3	$127K	Hold	8,293	–	–	0.05%	9
2021 Q2	$148K	Hold	8,293	–	–	0.05%	9
2021 Q1	$148K	Hold	8,293	–	–	0.04%	11
2020 Q4	$128K	Hold	8,293	–	–	0.02%	12
2020 Q3	$92K	Hold	8,293	–	–	0.03%	11
2020 Q2	$104K	Hold	8,293	–	–	0.09%	10
2020 Q1	$94K	Hold	8,293	–	–	0.1%	11
2019 Q4	$109K	Hold	8,293	–	–	0.05%	11
2019 Q3	$75K	Hold	8,293	–	–	0.03%	12
2019 Q2	$82K	Hold	8,293	–	–	0.03%	12
2019 Q1	$84K	Hold	8,293	–	–	0.08%	11
2018 Q4	$52K	Hold	8,293	–	–	0.07%	11
2018 Q3	$109K	Hold	8,293	–	–	0.05%	11
2018 Q2	$76K	Hold	8,293	–	–	0.03%	12
2018 Q1	$23K	Hold	8,293	–	–	0.01%	11
2017 Q4	$23K	Hold	8,293	–	–	0.01%	11
2017 Q3	$24K	Hold	8,293	–	–	0.01%	10
2017 Q2	$26K	Hold	8,293	–	–	0.01%	12
2017 Q1	$33K	Sell	8,293 -311,768	-97%	-$2.45M	0.01%	12
2016 Q4	$2.46M	Buy	+320,061	New	+$2.57M	0.59%	11

Other funds holding XENE

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

InterWest Venture Management's XENE Position: Q4 2021 in Review

InterWest Venture Management sold out of Xenon Pharmaceuticals (XENE) in Q4 2021, closing a stake of 8,293 shares — an estimated $127K sold.

InterWest Venture Management first reported a position in XENE in Q4 2016 and held it in 20 quarters. The position peaked at $2.46M in Q4 2016. 130 funds tracked by Wall St. Rank hold XENE as of Q4 2021.

InterWest Venture Management reported no remaining Xenon Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
InterWest Venture Management sold 8,293 Xenon Pharmaceuticals shares in Q4 2021, an estimated $127K.
InterWest Venture Management first reported a position in Xenon Pharmaceuticals in Q4 2016 and held it in 20 quarters.
InterWest Venture Management's Xenon Pharmaceuticals position peaked at $2.46M in Q4 2016.
130 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q4 2021.

Based on InterWest Venture Management's 13F filing for Q4 2021, filed 25 Jan 2022.